Frontlight ResearchEarly access
Active, not recruitingNo phase
Comparison of TAVR With SAVR in Younger Low Surgical Risk Patients With Severe Aortic Stenosis
Key facts
- Who runs it
- Ole De Backer
- Where
- Denmark, Finland, Iceland, Norway, and Sweden9 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 376 people enrolled
- Started
- 30 Jun 2016
- Expected to end
- Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transcatheter aortic valve replacement
- Surgical aortic valve replacement
- Record updated
- 9 April 2024
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age 75 years or younger
- Severe calcific AS (Valve area <1cm2 (or <0.6 cm2/m2) AND one of the two following criteria: mean gradient >40mmHg or peak jet velocity >4.0m/s, OR in presence of low flow, low gradient with reduced or normal LVEF<50%, a dobutamine stress echo should verify true severe AS rather than pseudo-AS
- Symptomatic with angina pectoris, dyspnea or exercise-induced syncope or near syncope OR asymptomatic with abnormal exercise test showing symptoms on exercise clearly related to AS or systolic LV dysfunction (LVEF <50%) not due to another cause
- Anticipated usage of biological aortic valve prosthesis
- Low risk for conventional surgery (STS Score <4%)
- Suitable for both SAVR and transfemoral TAVR
- Life expectancy >1 year after the intervention
- Informed consent to participate in the study after adequate information about the study before randomization and intervention
Who cannot take part
- Coronary artery disease, not suitable for both percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG)
- Porcelain aorta, which prevents open-heart surgery
- Need for open heart surgery other than SAVR with or without CABG
- Myocardial infarction within last 30 days
- Stroke or TIA within the last 30 days. NOTION-2, 01. February 2017, version 5 9
- Ongoing severe infection requiring intravenous antibiotics
- Unstable pre-procedural condition requiring intravenous inotropes or mechanical assist device (IABP, Impella) on the day of intervention
- Kidney disease requiring dialysis or severely impaired lung function (FEV1 and/or diffusion capacity <40% of predicted)
- Allergy to heparin, iodid contrast agent, warfarin, aspirin or clopidogrel
- LVEF <25% without contractile reserve during dobutamine stress echocardiography
- Coronary angiogram with a SYNTAX-score >22
- Bicuspid valve with aorta ascendens diameter ≥45mm
- Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR
- Current endocarditis, intracardiac tumor, thrombus or vegetation
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomized clinical trial investigating transcatheter (TAVR) versus surgical (SAVR) aortic valve replacement in patients 75 years of age or younger suffering from severe aortic valve stenosis.
Read full original descriptionShow less
Study hypothesis: The clinical outcome (death of any cause, stroke and rehospitalization (related to the procedure, valve or heart failure)) obtained within one year after TAVR is non-inferior to SAVR.
The 2 groups in the trial
- Transcatheter aortic valve replacementTreatment being tested
- Surgical aortic valve replacementExisting treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Nordic Aortic Valve Intervention Trial 2 - A Randomized Multicenter Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis
- Publications
- Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis.Circulation, 2025
- The low-risk TAVR trials-A critical appraisal of the current landscape.American heart journal, 2026
- Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial.European heart journal, 2024
- Record updated
- 9 April 2024